Irritable bowel syndrome: A review and update

Clinics in Colon and Rectal Surgery

Volumn 25, Issue 1, 2012, Pages 46-52

  Occhipinti, Kaitlin ^a   Smith, James W ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

functional gastrointestinal disease; irritable bowel syndrome

Indexed keywords

EID: 84862804834     PISSN: 15310043     EISSN: 15309681     Source Type: Journal    
DOI: 10.1055/s-0032-1301759     Document Type: Review

References (40)

1. Horwitz BJ, Fisher RS. The irritable bowel syndrome. N Engl J Med: 2001; 344 24 1846 1850 (Pubitemid 32538699)
2. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology: 2002; 123 6 2108 2131 (Pubitemid 35408332)
3. Whitehead WE, Burnett CK, Cook EW III, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci: 1996; 41 11 2248 2253 (Pubitemid 26414448)
4. Drossman DA, Li Z, Andruzzi E., et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci: 1993; 38 9 1569 1580 (Pubitemid 23271409)
5. Brandt LJ, Bjorkman D, Fennerty MB., et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol: 2002; 97 11, Suppl S7 S26
6. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ: 1978; 2 6138 653 654 (Pubitemid 9004104)
7. Drossman DA, Corazziari E, Talley NJ., et al. Rome II: The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology, and Treatment: A Multinational Consensus. 2nd ed. McLean, VA Degnon Associates: 2000
8. Brandt LJ, Chey WD, Foxx-Orenstein AE., et al. American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol: 2009; 104 Suppl 1 S1 S35
9. Sanders DS, Carter MJ, Hurlstone DP., et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet: 2001; 358 9292 1504 1508 (Pubitemid 33055702)
10. Biesiekierski JR, Newnham ED, Irving PM., et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol: 2011; 106 3 508 514, quiz 515
11. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med: 1995; 122 2 107 112
12. Drossman DA. Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med: 1995; 123 9 688 697
13. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet: 1987; 1 8539 963 965 (Pubitemid 17055976)
14. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol: 2002; 97 11 2812 2819 (Pubitemid 35265433)
15. Ong DK, Mitchell SB, Barrett JS., et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol: 2010; 25 8 1366 1373
16. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med: 2000; 133 2 136 147 (Pubitemid 30490414)
17. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut: 2001; 48 2 272 282 (Pubitemid 32141856)
18. Talley NJ. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol: 2003; 98 4 750 758 (Pubitemid 36576297)
19. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther: 2001; 15 3 355 361 (Pubitemid 32187557)
20. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol: 1981; 3 2 153 156 (Pubitemid 11113503)
21. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci: 1995; 40 1 86 95
22. Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology: 1997; 112 5 1714 1743 (Pubitemid 27181399)
23. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther: 1994; 8 4 409 416 (Pubitemid 24257557)
24. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut: 2009; 58 3 367 378
25. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet: 1994; 344 8914 39 40 (Pubitemid 24199426)
26. Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ: 2009; 339 b3154
27. Drossman DA, Chey WD, Johanson JF., et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndromeresults of two randomized, placebo-controlled studies. Aliment Pharmacol Ther: 2009; 29 3 329 341
28. Zighelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci: 1995; 40 4 819 827
29. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol: 2000; 95 12 3503 3506
30. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol: 2003; 98 2 412 419 (Pubitemid 36232393)
31. Pimentel M, Lembo A, Chey WD., et al. TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med: 2011; 364 1 22 32
32. Spanier JA, Howden CW, Jones MP. A systematic review of alternative therapies in the irritable bowel syndrome. Arch Intern Med: 2003; 163 3 265 274 (Pubitemid 36183854)
33. Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci: 2010; 55 5 1385 1390
34. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis: 2007; 39 6 530 536 (Pubitemid 46746646)
35. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol: 1997; 32 6 765 768
36. Quigley E, Fried M, Gwee KA., et al. Irritable Bowel Syndrome: A Global Perspective. World Gastroenterology Organisation Global Guideline. Munich, Germany World Gastroenterology Organisation: 2009
37. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol: 2009; 104 4 1033 1049, quiz 1050
38. Gaylord SA, Palsson OS, Garland EL., et al. Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Am J Gastroenterol: 2011; 106 9 1678 1688
39. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology: 2000; 119 3 654 660
40. Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care: 1988; 26 7 724 735